Image For Activity Cover
Diabetes Strategies for Primary Care
Info and Disclaimers

Learning Objectives

Upon completion of the activity, participants should be able to:

  • Identify important research published in the past year regarding diabetes pharmacotherapy, cardiovascular and renal outcomes, inpatient diabetes management, diabetes technology, and access to healthcare
  • Review results of recent randomized control trials on the safety and efficacy of antidiabetic agents for cardiovascular and renal protection and identify AACE recommendations for the management of obesity, hypertension, hyperlipidemia and cardiovascular risk factors in patients with diabetes
  • Assess the current issues and challenges with SGLT2 inhibitors
  • Describe noninvasive tests used for identification of patients with NAFLD, NASH and identify those who are at high risk for clinically significant liver fibrosis

Accreditation

Target Audience

This educational initiative is intended for the Primary Care Team.

Accreditation Statement

The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Endocrinology designates this enduring activity for a maximum of 8.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.5 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Disclosures/Conflicts of Interest

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.

 

 

Faculty Disclosures

 

First

MI

Last

Credentials

Position

Institution

Role

Disclosure(s)

Cecilia

C.

Low Wang

MD

Professor of Medicine

University of Colorado Anschutz Medical Campus School of Medicine

Speaker/Moderator

Dexcom Inc (Self) : Research Grant (Status: Ongoing)

Rifka

 

Schulman-Rosenbaum

MD, FACE, CNSC

Director of Inpatient Diabetes, Associate Professor of Medicine

Division of Endocrinology, Diabetes and Metabolism Long Island Jewish Medical Center, and Barbara Zucker School of Medicine at Hofstra/Northwell

Speaker/Moderator

Nothing to disclose

Lawrence

 

Blonde

MD, FACP, MACE

Physician

Ochsner Medical Center

Speaker

AstraZeneca (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- No activities in the past 24 months); Corcept (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Gilead Sciences, Inc. (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing); Janssen () : Honorarium, speaker; Lyndra Therapeutics (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Merck & Co (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Salix (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Sanofi (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing), Research Grant (Status: Ongoing)

Guillermo

E.

Umpierrez

MD, MACP, CDCES, FACE

Professor of Medicine

Emory University

Speaker/Moderator

Astra Zeneca (Self) : Grant support to Emory University for investigator-initiated clinical studies (Status: Ongoing), University Grants/Research Support (Status: Ongoing); Dexcom (Self) : University Grants/Research Support (Status: Ongoing); Novo Nordisk (Self) : Grant support to Emory University for investigator-initiated clinical studies (Status: Terminated --- December 2020), University Grants/Research Support (Status: Terminated --- December 2020); Sanofi,Merck, Novo Nordisk, Astra Zeneca, Boehringer Ingelheim (Self) : Received grant support (to Emory university) for investigator-initiated research studies from Sanofi, Novo Nordisk, Astra Zeneca, Merck and Boehringer Ingelheim. (Status: Terminated --- January 2019), Research Grant (Status: Terminated --- January 2019)

Archana

 

Sadhu

MD, FACE

Director, System Diabetes Program and Director, Transplant Endocrinology

Houston Methodist

Speaker

Abbott (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

Rodolfo

J.

Galindo

MD, FACE

 

Emory University

Speaker

Abbott Diabetes (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 12/31/2018); Dexcom (Self) : University Grants/Research Support (Status: Ongoing); Eli Lilly (Self) : Research Grant (Status: Ongoing); Novo Nordisk (Self) : University Grants/Research Support (Status: Ongoing); Sanofi (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Valeritas (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 12/31/2019); Weight Watchers (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

Neda

 

Rasouli

MD

 

University of Colorado 

Moderator

Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)

Katherine

R.

Tuttle

MD, FASN, FACP, FNKF

Professor of Medicine

University of Washington

Speaker

AstraZeneca (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Bayer (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Boehringer Ingelheim (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Eli Lilly (Self) : Honorarium (Status: Ongoing); Gilead (Self) : Grant/Research Support (Status: Ongoing); Goldfinch Bio (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Grant/Research Support (Status: Ongoing); Travere (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)

Natasa

 

Janicic Kahric

MD

Associate Professor

Medstar Georgetown University Hospital

Speaker

DEXCOM (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

Scott

D.

Isaacs

MD, FACP, FACE

Adjunct Assistant Professor of Medicine

Emory University School of Medicine

Speaker

Madrigal (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21); Medpace (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21); Quest (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21)

Kenneth

 

Cusi

MD, FACP, FACE

Chief of the Division of Endocrinology

UFL

Speaker

Allergan Pharmaceuticals (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); AstraZeneca (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Axcellla (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); BMS (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Boehringer Ingelheim (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Cirius (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Coherus (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Deuterex (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Echosens (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Eli Lilly (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Fractyl (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Genentech (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Genfit (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); High Tide (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2021); Inventiva (Self) : Grant/Research Support (Status: Ongoing), Research Grant (Status: Ongoing); Janssen (Self) : Research Grant (Status: Terminated --- 2020); Madrigal (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Merck (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); National Institutes of Health (Self) : Grant/Research Support (Status: Ongoing), Research Grant (Status: Ongoing); Nordic (Self) : Research Support (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Poxel (Self) : Research Grant (Status: Terminated --- 2021); Prosciento (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Sanofi-Adventis (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2020); Viscera Labs (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2020); Zydus (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)

 

 

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The American Association of Clinical presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The American Association of Clinical Endocrinology assumes no liability for the information herein.

Summary
Availability: On-Demand
Cost: FREE
Credit Offered:
8.5 CME Credits
8.5 ABIM-MOC Points
Powered By